Loading patent…
AssigneeSichuan Kelun Pharmaceutical Research Institute Co., Ltd.
InventorsJiao ZHANG, Xiaobo MA, Tianming WANG, Gao WANG, Wenhao LI, Zhou SHI, Junzhu PAN, Chengxi YANG, Dong ZHAO, Sichuan LIU
Estimating the term…
The present application discloses a crystal form of a muscarine antagonist, a method for preparing same, and use thereof, and particularly, a crystal form A of revefenacin. The crystal form A of revefenacin comprises an X-ray powder diffraction pattern having characteristic peaks at diffraction angles 2θ of 4.7±0.2, 9.2±0.2, 12.7±0.2, 18.2±0.2, 18.5±0.2, 20.7±0.2, 21.3±0.2, and 25.6±0.2. The crystal form of the present disclosure features a regular sheet shape, a high crystallinity, a high dissolution rate, and high fluidity and bulk density.
A crystal form A of revefenacin, wherein the crystal form A of revefenacin comprises an X-ray powder diffraction pattern having characteristic peaks at diffraction angles 2θ of 4.7±0.2°, 9.2±0.2°, 12.7±0.2°, 18.2±0.2°, 18.5±0.2°, 20.7±0.2°, 21.3±0.2° and 25.6±0.2°.
A revefenacin hydrate single crystal, wherein the single crystal belongs to the triclinic crystal system and has a space group of P-1, with crystal axes a=9.5522 (4) Å, b=9.9096 (4) Å, and c=18.3690 (9) Å, interaxial angles α=86.419 (4)°, β=86.906 (4)°, and γ=89.544 (3)°, a Z value of 2 for the number of asymmetric units per unit cell, and each unit cell containing one revefenacin molecule and three water molecules.
(canceled)
Dependencies are inferred from the claim text.